Search Results - "Dargatz, P."

HLA-DR expression on monocytes is decreased in polytraumatized patients by Vester, Helen, Dargatz, P, Huber-Wagner, S, Biberthaler, P, van Griensven, M

“…Sepsis, systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) remain the most frequent causes of complications and…”
Get full text

959P - A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH) by Grünwald, V., Grüllich, C., Ivanyi, P., Wirth, M., Staib, P., Schostak, M., Dargatz, P., Müller, L., Metz, M., Bergmann, L., Welslau, M.K., Schütt, P., Rafiyan, M.-R., Hellmis, E., Hinke, A., Meiler, J., Kretz, T., Loidl, W.C., Flörcken, A., Steiner, T.

“…Tyrosine kinase inhibitors (TKI) and nivolumab (NIVO) are key components of systemic therapies in metastatic renal cell carcinoma (mRCC). We tested if TKI…”
Get full text

A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH) by Grünwald, V., Grüllich, C., Ivanyi, P., Wirth, M., Staib, P., Schostak, M., Dargatz, P., Müller, L., Metz, M., Bergmann, L., Welslau, M.K., Schütt, P., Rafiyan, M.-R., Hellmis, E., Hinke, A., Meiler, J., Kretz, T., Loidl, W.C., Flörcken, A., Steiner, T.

Get full text

959PA phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH) by Grünwald, V, Grüllich, C, Ivanyi, P, Wirth, M, Staib, P, Schostak, M, Dargatz, P, Müller, L, Metz, M, Bergmann, L, Welslau, M K, Schütt, P, Rafiyan, M-R, Hellmis, E, Hinke, A, Meiler, J, Kretz, T, Loidl, W C, Flörcken, A, Steiner, T

“…Abstract Background Tyrosine kinase inhibitors (TKI) and nivolumab (NIVO) are key components of systemic therapies in metastatic renal cell carcinoma (mRCC)…”
Get full text